TMCnet News
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual MeetingSOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington. ARVO 2024 Presentation Details: Title: Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up Title: Senolytic drug candidate in wet AMD demonstrates benefit with Multifocal ERG testing Additional presentation details and abstracts are available on the ARVO 2024 website here. About UNITY Media Contact Investor Contact |